Cure: Sergey Jakimov and Artem Trotsyuk on Why Aging Still Has No Measuring Stick
LongeVC managing partner Sergey Jakimov and operating partner Artem Trotsyuk spoke to Jessica Orwig at Cure about one of the field's biggest open problems: there is still no validated way to measure whether a drug is slowing human aging.
The article centers on FAST, an ARPA-H backed initiative led by Daniel Belsky, Nir Barzilai and Mahdi Moqri, which is mining completed clinical trials for molecular signals of aging that hold up across very different interventions.
Sergey shared the question we ask companies that claim to have moved an aging biomarker: which FDA process are you going through, and what is the indication? Artem asked what happens if FAST succeeds, and whether aging could then become an indication the FDA recognizes. Sergey added that reliable biomarkers would also draw new investors into longevity biotech.